10x Genomics, Inc. Quarterly Operating Income (Loss) in USD from Q3 2018 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: 10x Genomics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2018 to Q3 2024.
10x Genomics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$41.5M, a 56.2% increase year-over-year.
10x Genomics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$200M, a 14.3% increase year-over-year.
10x Genomics, Inc. annual Operating Income (Loss) for 2023 was -$265M, a 58% decline from 2022.
10x Genomics, Inc. annual Operating Income (Loss) for 2022 was -$168M, a 221% decline from 2021.
10x Genomics, Inc. annual Operating Income (Loss) for 2021 was -$52.3M, a 90.2% increase from 2020.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2024	-$200M	-$41.5M	+$53.3M	+56.2%	Jul 1, 2024	Sep 30, 2024	10-Q	2024-10-29
Q2 2024	-$253M	-$41.7M	+$21.6M	+34.1%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-08
Q1 2024	-$275M	-$61.5M	-$9.51M	-18.3%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-04-30
Q4 2023	-$265M	-$55.2M	-$32.1M	-139%	Oct 1, 2023	Dec 31, 2023	10-K	2024-02-15
Q3 2023	-$233M	-$94.8M	-$54.8M	-137%	Jul 1, 2023	Sep 30, 2023	10-Q	2024-10-29
Q2 2023	-$178M	-$63.4M	-$241K	-0.38%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-08
Q1 2023	-$178M	-$52M	-$10.3M	-24.6%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-04-30
Q4 2022	-$168M	-$23.1M	-$7.27M	-45.9%	Oct 1, 2022	Dec 31, 2022	10-K	2024-02-15
Q3 2022	-$161M	-$40M	-$24.1M	-152%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-03
Q2 2022	-$137M	-$63.1M	-$52.8M	-511%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-04
Q1 2022	-$83.8M	-$41.7M	-$31.5M	-309%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-04
Q4 2021	-$52.3M	-$15.8M	+$394M	+96.1%	Oct 1, 2021	Dec 31, 2021	10-K	2024-02-15
Q3 2021	-$446M	-$15.9M	+$49.4M	+75.7%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-03
Q2 2021	-$495M	-$10.3M	+$29.1M	+73.8%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-09
Q1 2021	-$524M	-$10.2M	+$9.67M	+48.6%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-05
Q4 2020	-$534M	-$410M	-$402M	-4969%	Oct 1, 2020	Dec 31, 2020	10-K	2023-02-16
Q3 2020	-$133M	-$65.3M	-$56.2M	-617%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-05
Q2 2020	-$76.5M	-$39.4M	-$29.1M	-280%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-06
Q1 2020	-$47.4M	-$19.9M	-$16.8M	-555%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-07
Q4 2019	-$30.6M	-$8.08M			Oct 1, 2019	Dec 31, 2019	10-K	2022-02-18
Q3 2019		-$9.1M	+$5.84M	+39.1%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-12
Q2 2019		-$10.4M			Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-12
Q1 2019		-$3.04M			Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-12
Q3 2018		-$14.9M			Jul 1, 2018	Sep 30, 2018	10-Q	2019-11-12

* An asterisk sign (*) next to the value indicates that the value is likely invalid.